Malignant progression of SHH ligand-dependent tumors such as prostate adenocarcinomas would be inhibited by high Serpine2/PN-1 [36], while the malignancy of SHH ligand-independent tumors such as medulloblastomas (this study) and gastric cancer [64] would be aggravated. The gene discussed is SERPINE2; the disease is prostate adenocarcinoma.